HBD2 Therapeutic Patent for Preterm NEC, Apr 15
Summary
EPO published patent application EP3706773A2 titled 'HBD2 FOR USE IN THE TREATMENT OF NECROTISING ENTEROCOLITIS IN A PRETERM INFANT' on April 15, 2026. The applicant is Defensin Therapeutics ApS with inventor Peter Nordkild. The application covers the therapeutic use of HBD2 (human beta-defensin 2) for treating necrotizing enterocolitis in preterm infants. The designated states cover all major European patent convention member states including DE, FR, GB, IT, NL, SE, and others.
About this source
GovPing monitors EPO Patent Bulletin - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 36 changes logged to date.
What changed
EPO published patent application EP3706773A2 for HBD2 (human beta-defensin 2) for use in treating necrotising enterocolitis in preterm infants. The application names Defensin Therapeutics ApS as applicant and Peter Nordkild as inventor. The publication is classified as Kind A2 (European application with international search report). Designated states include all major EPC contracting states.
For pharmaceutical companies developing neonatal therapeutics, this patent application signals potential competitive landscape considerations for HBD2-based treatments for necrotising enterocolitis. Defensin Therapeutics ApS has staked a territorial claim across all major European markets for this specific therapeutic indication. Parties researching or developing antimicrobial peptide therapeutics for neonatal applications should review freedom-to-operate implications.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
HBD2 FOR USE IN THE TREATMENT OF NECROTISING ENTEROCOLITIS IN A PRETERM INFANT
Publication EP3706773A2 Kind: A2 Apr 15, 2026
Applicants
Defensin Therapeutics ApS
Inventors
NORDKILD, Peter
IPC Classifications
A61K 38/17 20060101AFI20200604BHEP A61P 1/00 20060101ALI20200604BHEP A61P 11/00 20060101ALI20200604BHEP A61P 1/12 20060101ALI20200604BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.